You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAdenosine triphosphate
Accession NumberDB00171  (EXPT00007, NUTR00017)
TypeSmall Molecule
GroupsApproved, Nutraceutical
Description

An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
Adenosine 5'-triphosphateNot AvailableNot Available
Adenosine-5'-triphosphateNot AvailableNot Available
ATPNot AvailableNot Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
AtriphosBiochimica
StriadyneAuclair
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number56-65-5
WeightAverage: 507.181
Monoisotopic: 506.995745159
Chemical FormulaC10H16N5O13P3
InChI KeyZKHQWZAMYRWXGA-YPLCUDRINA-N
InChI
InChI=1/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/s2
IUPAC Name
({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid
SMILES
NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as purine ribonucleoside triphosphates. These are purine ribobucleotides with a triphosphate group linked to the ribose moiety.
KingdomOrganic compounds
Super ClassNucleosides, nucleotides, and analogues
ClassPurine nucleotides
Sub ClassPurine ribonucleotides
Direct ParentPurine ribonucleoside triphosphates
Alternative Parents
Substituents
  • Purine ribonucleoside triphosphate
  • N-glycosyl compound
  • Glycosyl compound
  • Organic pyrophosphate
  • Monosaccharide phosphate
  • 6-aminopurine
  • Purine
  • Imidazopyrimidine
  • Monoalkyl phosphate
  • Aminopyrimidine
  • Imidolactam
  • Alkyl phosphate
  • Pyrimidine
  • Primary aromatic amine
  • Phosphoric acid ester
  • Organic phosphoric acid derivative
  • Organic phosphate
  • N-substituted imidazole
  • Monosaccharide
  • Saccharide
  • Heteroaromatic compound
  • Oxolane
  • Imidazole
  • Azole
  • Secondary alcohol
  • 1,2-diol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor nutritional supplementation, also for treating dietary shortage or imbalance
PharmacodynamicsAdenosine triphosphate (ATP) is the nucleotide known in biochemistry as the "molecular currency" of intracellular energy transfer; that is, ATP is able to store and transport chemical energy within cells. ATP also plays an important role in the synthesis of nucleic acids. The total quantity of ATP in the human body is about 0.1 mole. The energy used by human cells requires the hydrolysis of 200 to 300 moles of ATP daily. This means that each ATP molecule is recycled 2000 to 3000 times during a single day. ATP cannot be stored, hence its consumption must closely follow its synthesis.
Mechanism of actionATP is able to store and transport chemical energy within cells. ATP also plays an important role in the synthesis of nucleic acids. ATP can be produced by various cellular processes, most typically in mitochondria by oxidative phosphorylation under the catalytic influence of ATP synthase. The total quantity of ATP in the human body is about 0.1 mole. The energy used by human cells requires the hydrolysis of 200 to 300 moles of ATP daily. This means that each ATP molecule is recycled 2000 to 3000 times during a single day. ATP cannot be stored, hence its consumption must closely follow its synthesis.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOral LD50 in rats is > 2 g/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Tenofovir Action PathwayDrug actionSMP00419
Adefovir Dipivoxil Action PathwayDrug actionSMP00418
Erlotinib Action PathwayDrug actionSMP00472
Vindesine Action PathwayDrug actionSMP00438
Vincristine Action PathwayDrug actionSMP00437
Trehalose DegradationMetabolicSMP00467
Paclitaxel Action PathwayDrug actionSMP00434
Docetaxel Action PathwayDrug actionSMP00435
Biotinidase DeficiencyDiseaseSMP00174
Lactose IntoleranceDiseaseSMP00458
Vinorelbine Action PathwayDrug actionSMP00439
Glibenclamide Action PathwayDrug actionSMP00460
Excitatory Neural Signalling Through 5-HTR 4 and SerotoninSignalingSMP00309
Adefovir Dipivoxil Metabolism PathwayDrug metabolismSMP00629
Emtricitabine Action PathwayDrug actionSMP00741
Nevirapine Action PathwayDrug actionSMP00743
Beta Oxidation of Very Long Chain Fatty AcidsMetabolicSMP00052
Clopidogrel Action PathwayDrug actionSMP00260
Repaglinide Action PathwayDrug actionSMP00454
Joubert syndromeDiseaseSMP00582
Gastric Acid ProductionPhysiologicalSMP00589
Efavirenz Action PathwayDrug actionSMP00740
Zidovudine Action PathwayDrug actionSMP00747
Lactose DegradationMetabolicSMP00457
Gemcitabine Action PathwayDrug actionSMP00446
Nateglinide Action PathwayDrug actionSMP00453
Excitatory Neural Signalling Through 5-HTR 6 and Serotonin SignalingSMP00312
Intracellular Signalling Through Histamine H2 Receptor and HistamineSignalingSMP00335
Multiple carboxylase deficiency, neonatal or early onset formDiseaseSMP00564
Muscle/Heart ContractionPhysiologicalSMP00588
Zalcitabine Action PathwayDrug actionSMP00746
Biotin MetabolismMetabolicSMP00066
Vinblastine Action PathwayDrug actionSMP00436
Excitatory Neural Signalling Through 5-HTR 7 and Serotonin SignalingSMP00311
Intracellular Signalling Through FSH Receptor and Follicle Stimulating HormoneSignalingSMP00333
Intracellular Signalling Through LHCGR Receptor and Luteinizing Hormone/ChoriogonadotropinSignalingSMP00338
Carnitine-acylcarnitine translocase deficiencyDiseaseSMP00517
Pancreas FunctionPhysiologicalSMP00643
Delavirdine Action PathwayDrug actionSMP00738
Stavudine Action PathwayDrug actionSMP00745
Thiamine MetabolismMetabolicSMP00076
Inositol Phosphate MetabolismMetabolicSMP00462
Phosphatidylinositol Phosphate MetabolismMetabolicSMP00463
Gliclazide Action PathwayDrug actionSMP00461
Corticotropin Activation of Cortisol ProductionSignalingSMP00310
Vasopressin Regulation of Water HomeostasisSignalingSMP00322
Adrenoleukodystrophy, X-linkedDiseaseSMP00516
Gemcitabine Metabolism PathwayDrug metabolismSMP00603
Clopidogrel Metabolism PathwayDrug metabolismSMP00610
Tenofovir Metabolism PathwayDrug metabolismSMP00630
Nevirapine Metabolism PathwayDrug metabolismSMP00642
Abacavir Action PathwayDrug actionSMP00737
Lamivudine Action PathwayDrug actionSMP00742
Rilpivirine Action PathwayDrug actionSMP00744
Rabeprazole Action PathwayDrug actionSMP00229
Famotidine Action PathwayDrug actionSMP00231
Acebutolol Action PathwayDrug actionSMP00296
Esmolol Action PathwayDrug actionSMP00301
Nadolol Action PathwayDrug actionSMP00303
Quinidine Action PathwayDrug actionSMP00323
Tocainide Action PathwayDrug actionSMP00330
Carvedilol Action PathwayDrug actionSMP00367
Verapamil Action PathwayDrug actionSMP00375
Nimodipine Action PathwayDrug actionSMP00380
Timolol Action PathwayDrug actionSMP00659
Levobunolol Action PathwayDrug actionSMP00666
Betazole Action PathwayDrug actionSMP00736
Irinotecan Action PathwayDrug actionSMP00433
Esomeprazole Action PathwayDrug actionSMP00225
Cimetidine Action PathwayDrug actionSMP00232
Alprenolol Action PathwayDrug actionSMP00297
Oxprenolol Action PathwayDrug actionSMP00304
Procainamide (Antiarrhythmic) Action PathwayDrug actionSMP00324
Flecainide Action PathwayDrug actionSMP00331
Labetalol Action PathwayDrug actionSMP00368
Amlodipine Action PathwayDrug actionSMP00376
Nisoldipine Action PathwayDrug actionSMP00381
Sotalol Action PathwayDrug actionSMP00660
Metipranolol Action PathwayDrug actionSMP00667
Transfer of Acetyl Groups into MitochondriaMetabolicSMP00466
Pantoprazole Action PathwayDrug actionSMP00228
Ranitidine Action PathwayDrug actionSMP00230
Bisoprolol Action PathwayDrug actionSMP00300
Metoprolol Action PathwayDrug actionSMP00302
Propranolol Action PathwayDrug actionSMP00307
Mexiletine Action PathwayDrug actionSMP00329
Nebivolol Action PathwayDrug actionSMP00366
Nifedipine Action PathwayDrug actionSMP00379
Dopamine Activation of Neurological Reward SystemSignalingSMP00308
Intracellular Signalling Through Prostacyclin Receptor and ProstacyclinSignalingSMP00354
Amiodarone Action PathwayDrug actionSMP00665
Bupranolol Action PathwayDrug actionSMP00670
Metiamide Action PathwayDrug actionSMP00735
Phenylacetate MetabolismMetabolicSMP00126
Lansoprazole Action PathwayDrug actionSMP00227
Pirenzepine Action PathwayDrug actionSMP00246
Betaxolol Action PathwayDrug actionSMP00299
Pindolol Action PathwayDrug actionSMP00306
Diltiazem Action PathwayDrug actionSMP00359
Isradipine Action PathwayDrug actionSMP00378
Intracellular Signalling Through PGD2 receptor and Prostaglandin D2SignalingSMP00343
Irinotecan Metabolism PathwayDrug metabolismSMP00600
Carteolol Action PathwayDrug actionSMP00658
Dobutamine Action PathwayDrug actionSMP00662
Arbutamine Action PathwayDrug actionSMP00664
Practolol Action PathwayDrug actionSMP00669
Roxatidine acetate Action PathwayDrug actionSMP00734
Didanosine Action PathwayDrug actionSMP00739
Mitochondrial Beta-Oxidation of Short Chain Saturated Fatty AcidsMetabolicSMP00480
Omeprazole Action PathwayDrug actionSMP00226
Nizatidine Action PathwayDrug actionSMP00233
Atenolol Action PathwayDrug actionSMP00298
Penbutolol Action PathwayDrug actionSMP00305
Disopyramide Action PathwayDrug actionSMP00325
Ibutilide Action PathwayDrug actionSMP00332
Felodipine Action PathwayDrug actionSMP00377
Nitrendipine Action PathwayDrug actionSMP00382
Short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (SCHAD)DiseaseSMP00568
Bopindolol Action PathwayDrug actionSMP00657
Epinephrine Action PathwayDrug actionSMP00661
Isoprenaline Action PathwayDrug actionSMP00663
Bevantolol Action PathwayDrug actionSMP00668
Glycerolipid MetabolismMetabolicSMP00039
Proparacaine Action PathwayDrug actionSMP00403
Hydromorphone Action PathwayDrug actionSMP00410
Sufentanil Action PathwayDrug actionSMP00417
D-glyceric aciduraDiseaseSMP00529
Tramadol Metabolism PathwayDrug metabolismSMP00637
Lamivudine Metabolism PathwayDrug metabolismSMP00649
Propoxyphene Action PathwayDrug actionSMP00672
Anileridine Action PathwayDrug actionSMP00674
3-Methylthiofentanyl Action PathwayDrug actionSMP00679
Pentazocine Action PathwayDrug actionSMP00686
Nalbuphine Action PathwayDrug actionSMP00691
Mitochondrial Beta-Oxidation of Medium Chain Saturated Fatty AcidsMetabolicSMP00481
Glycerol Kinase DeficiencyDiseaseSMP00187
Fosphenytoin (Antiarrhythmic) Action PathwayDrug actionSMP00326
Benzocaine Action PathwayDrug actionSMP00392
Cocaine Action PathwayDrug actionSMP00395
Oxybuprocaine Action PathwayDrug actionSMP00400
Oxymorphone Action PathwayDrug actionSMP00412
Carfentanil Action PathwayDrug actionSMP00414
Desipramine Action PathwayDrug actionSMP00423
Dezocine Action PathwayDrug actionSMP00676
Ethylmorphine Action PathwayDrug actionSMP00681
Levallorphan Action PathwayDrug actionSMP00683
Naloxone Action PathwayDrug actionSMP00688
Chloroprocaine Action PathwayDrug actionSMP00394
Mepivacaine Action PathwayDrug actionSMP00399
Morphine Action PathwayDrug actionSMP00406
Hydrocodone Action PathwayDrug actionSMP00411
Familial lipoprotein lipase deficiencyDiseaseSMP00530
Doxorubicin Metabolism PathwayDrug metabolismSMP00650
Diphenoxylate Action PathwayDrug actionSMP00675
Dimethylthiambutene Action PathwayDrug actionSMP00680
Naltrexone Action PathwayDrug actionSMP00687
Inositol MetabolismMetabolicSMP00011
Levobupivacaine Action PathwayDrug actionSMP00397
Procaine Action PathwayDrug actionSMP00402
Ropivacaine Action PathwayDrug actionSMP00404
Oxycodone Action PathwayDrug actionSMP00409
Remifentanil Action PathwayDrug actionSMP00416
Escitalopram Action PathwayDrug actionSMP00425
Intracellular Signalling Through Adenosine Receptor A2b and AdenosineSignalingSMP00321
Tramadol Action Action PathwayDrug actionSMP00671
Levorphanol Action PathwayDrug actionSMP00673
Methadyl Acetate Action PathwayDrug actionSMP00678
Alvimopan Action PathwayDrug actionSMP00685
Ketobemidone Action PathwayDrug actionSMP00690
Threonine and 2-Oxobutanoate DegradationMetabolicSMP00452
Bupivacaine Action PathwayDrug actionSMP00393
Dibucaine Action PathwayDrug actionSMP00396
Prilocaine Action PathwayDrug actionSMP00401
Alfentanil Action PathwayDrug actionSMP00413
Fentanyl Action PathwayDrug actionSMP00415
Intracellular Signalling Through Adenosine Receptor A2a and AdenosineSignalingSMP00320
Acetaminophen Metabolism PathwayDrug metabolismSMP00640
Levomethadyl Acetate Action Action PathwayDrug actionSMP00677
Buprenorphine Action PathwayDrug actionSMP00684
Dihydromorphine Action PathwayDrug actionSMP00689
Citric Acid CycleMetabolicSMP00057
Nucleotide Sugars MetabolismMetabolicSMP00010
Pentose Phosphate PathwayMetabolicSMP00031
Ethylmalonic EncephalopathyDiseaseSMP00181
Globoid Cell LeukodystrophyDiseaseSMP00348
Etoposide Action PathwayDrug actionSMP00442
Lidocaine (Local Anaesthetic) Action PathwayDrug actionSMP00398
Fluoxetine Action PathwayDrug actionSMP00426
Carnitine palmitoyl transferase deficiency (II)DiseaseSMP00541
Mitochondrial complex II deficiencyDiseaseSMP00548
Glycogenosis, Type III. Cori disease, Debrancher glycogenosisDiseaseSMP00553
Glycogenosis, Type VI. Hers diseaseDiseaseSMP00555
Phosphoenolpyruvate carboxykinase deficiency 1 (PEPCK1)DiseaseSMP00560
Fanconi-bickel syndromeDiseaseSMP00572
Glycogenosis, Type ICDiseaseSMP00574
Selenoamino Acid MetabolismMetabolicSMP00029
Butyrate MetabolismMetabolicSMP00073
Ethanol DegradationMetabolicSMP00449
Sulfate/Sulfite MetabolismMetabolicSMP00041
Short Chain Acyl CoA Dehydrogenase Deficiency (SCAD Deficiency)DiseaseSMP00235
Refsum DiseaseDiseaseSMP00451
GlycolysisMetabolicSMP00040
Mitochondrial Electron Transport ChainMetabolicSMP00355
Lidocaine (Antiarrhythmic) Action PathwayDrug actionSMP00328
Heroin Action PathwayDrug actionSMP00407
Glucose-6-phosphate dehydrogenase deficiencyDiseaseSMP00518
Krabbe diseaseDiseaseSMP00526
Glycogenosis, Type VII. Tarui diseaseDiseaseSMP00531
Carnitine palmitoyl transferase deficiency (I)DiseaseSMP00538
Trifunctional protein deficiencyDiseaseSMP00545
Pyruvate dehydrogenase deficiency (E3)DiseaseSMP00550
Sucrase-isomaltase deficiencyDiseaseSMP00557
Fructose-1,6-diphosphatase deficiencyDiseaseSMP00562
Glycogenosis, Type IA. Von gierke diseaseDiseaseSMP00581
Pantothenate and CoA BiosynthesisMetabolicSMP00027
Glutaric Aciduria Type IDiseaseSMP00185
GluconeogenesisMetabolicSMP00128
Metachromatic Leukodystrophy (MLD)DiseaseSMP00347
Phenytoin (Antiarrhythmic) Action PathwayDrug actionSMP00327
Imipramine Action PathwayDrug actionSMP00422
Fabry diseaseDiseaseSMP00525
Medium chain acyl-coa dehydrogenase deficiency (MCAD)DiseaseSMP00542
2-ketoglutarate dehydrogenase complex deficiencyDiseaseSMP00549
Mucopolysaccharidosis VI. Sly syndromeDiseaseSMP00556
Glycogenosis, Type IBDiseaseSMP00573
Fatty acid MetabolismMetabolicSMP00051
Riboflavin MetabolismMetabolicSMP00070
Sphingolipid MetabolismMetabolicSMP00034
Starch and Sucrose MetabolismMetabolicSMP00058
Oxidation of Branched Chain Fatty AcidsMetabolicSMP00030
Gaucher DiseaseDiseaseSMP00349
Galactosemia IIIDiseaseSMP00496
Transaldolase deficiencyDiseaseSMP00520
Very-long-chain acyl coa dehydrogenase deficiency (VLCAD)DiseaseSMP00540
Fumarase deficiencyDiseaseSMP00547
Glycogen synthetase deficiencyDiseaseSMP00552
Glycogenosis, Type IV. Amylopectinosis, Anderson diseaseDiseaseSMP00554
Phytanic Acid Peroxisomal OxidationMetabolicSMP00450
Mitochondrial Beta-Oxidation of Long Chain Saturated Fatty AcidsMetabolicSMP00482
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke DiseaseDiseaseSMP00374
Methadone Action PathwayDrug actionSMP00408
Galactosemia II (GALK)DiseaseSMP00495
Ribose-5-phosphate isomerase deficiencyDiseaseSMP00519
Sulfite oxidase deficiencyDiseaseSMP00532
Long chain acyl-CoA dehydrogenase deficiency (LCAD)DiseaseSMP00539
Congenital lactic acidosisDiseaseSMP00546
Pyruvate dehydrogenase deficiency (E2)DiseaseSMP00551
Triosephosphate isomeraseDiseaseSMP00563
Etoposide Metabolism PathwayDrug metabolismSMP00601
Valproic Acid Metabolism PathwayDrug metabolismSMP00635
Mycophenolic Acid Metabolism PathwayDrug metabolismSMP00652
Betaine MetabolismMetabolicSMP00123
Folate MetabolismMetabolicSMP00053
Histidine MetabolismMetabolicSMP00044
Steroid BiosynthesisMetabolicSMP00023
Propionic AcidemiaDiseaseSMP00236
3-Methylglutaconic Aciduria Type IIIDiseaseSMP00140
5-OxoprolinuriaDiseaseSMP00143
Chondrodysplasia Punctata II, X Linked Dominant (CDPX2)DiseaseSMP00388
HistidinemiaDiseaseSMP00191
Alendronate Action PathwayDrug actionSMP00095
Propanoate MetabolismMetabolicSMP00016
Nicotinate and Nicotinamide MetabolismMetabolicSMP00048
Familial Hypercholanemia (FHCA)DiseaseSMP00317
Malonic AciduriaDiseaseSMP00198
3-Methylglutaconic Aciduria Type IVDiseaseSMP00141
HypercholesterolemiaDiseaseSMP00209
Lovastatin Action PathwayDrug actionSMP00099
Cerivastatin Action PathwayDrug actionSMP00111
Codeine Action PathwayDrug actionSMP00405
Nicotine Action PathwayDrug actionSMP00431
Malonyl-coa decarboxylase deficiencyDiseaseSMP00502
Hyper-IgD syndromeDiseaseSMP00509
3-hydroxyisobutyric acid dehydrogenase deficiencyDiseaseSMP00521
Isovaleric acidemiaDiseaseSMP00524
Congenital disorder of glycosylation CDG-IIdDiseaseSMP00579
Cystinosis, ocular nonnephropathicDiseaseSMP00722
Fructose intolerance, hereditaryDiseaseSMP00725
Primary Hyperoxaluria Type IDiseaseSMP00352
Maple Syrup Urine DiseaseDiseaseSMP00199
Methylmalonic AciduriaDiseaseSMP00200
Smith-Lemli-Opitz Syndrome (SLOS)DiseaseSMP00389
Gamma-Glutamyltransferase DeficiencyDiseaseSMP00183
Simvastatin Action PathwayDrug actionSMP00082
Rosuvastatin Action PathwayDrug actionSMP00092
Cerebrotendinous Xanthomatosis (CTX)DiseaseSMP00315
Pamidronate Action PathwayDrug actionSMP00117
Beta-mercaptolactate-cysteine disulfiduriaDiseaseSMP00499
Wolman diseaseDiseaseSMP00511
Isobutyryl-coa dehydrogenase deficiencyDiseaseSMP00523
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)DiseaseSMP00543
Alanine MetabolismMetabolicSMP00055
Cysteine MetabolismMetabolicSMP00013
Fructose and Mannose DegradationMetabolicSMP00064
Spermidine and Spermine BiosynthesisMetabolicSMP00445
Lactose SynthesisMetabolicSMP00444
Valine, Leucine and Isoleucine DegradationMetabolicSMP00032
3-Hydroxy-3-Methylglutaryl-CoA Lyase DeficiencyDiseaseSMP00138
Methylmalonate Semialdehyde Dehydrogenase DeficiencyDiseaseSMP00384
Lysosomal Acid Lipase Deficiency (Wolman Disease)DiseaseSMP00319
Lactic AcidemiaDiseaseSMP00313
Ibandronate Action PathwayDrug actionSMP00079
Pravastatin Action PathwayDrug actionSMP00089
Bile Acid BiosynthesisMetabolicSMP00035
Zellweger SyndromeDiseaseSMP00316
Methylmalonic Aciduria Due to Cobalamin-Related DisordersDiseaseSMP00201
Tay-Sachs DiseaseDiseaseSMP00390
Sialuria or French Type SialuriaDiseaseSMP00217
Risedronate Action PathwayDrug actionSMP00112
Mevalonic aciduriaDiseaseSMP00510
3-hydroxyisobutyric aciduriaDiseaseSMP00522
FructosuriaDiseaseSMP00561
GLUT-1 deficiency syndromeDiseaseSMP00580
Amino Sugar MetabolismMetabolicSMP00045
Pyruvate Carboxylase DeficiencyDiseaseSMP00350
Beta-Ketothiolase DeficiencyDiseaseSMP00173
3-Methylcrotonyl Coa Carboxylase Deficiency Type IDiseaseSMP00237
Isovaleric AciduriaDiseaseSMP00238
CHILD SyndromeDiseaseSMP00387
Sialuria or French Type SialuriaDiseaseSMP00216
Galactose MetabolismMetabolicSMP00043
Congenital Bile Acid Synthesis Defect Type IIDiseaseSMP00314
GalactosemiaDiseaseSMP00182
Fluvastatin Action PathwayDrug actionSMP00119
Citalopram Action PathwayDrug actionSMP00424
5-oxoprolinase deficiencyDiseaseSMP00500
G(M2)-Gangliosidosis: Variant B, Tay-sachs diseaseDiseaseSMP00534
27-Hydroxylase DeficiencyDiseaseSMP00720
Glutathione MetabolismMetabolicSMP00015
2-Methyl-3-Hydroxybutryl CoA Dehydrogenase DeficiencyDiseaseSMP00137
3-Methylglutaconic Aciduria Type IDiseaseSMP00139
Glutathione Synthetase DeficiencyDiseaseSMP00337
DesmosterolosisDiseaseSMP00386
Salla Disease/Infantile Sialic Acid Storage DiseaseDiseaseSMP00240
Congenital Bile Acid Synthesis Defect Type IIIDiseaseSMP00318
Methotrexate Action PathwayDrug actionSMP00432
Zoledronate Action PathwayDrug actionSMP00107
Atorvastatin Action PathwayDrug actionSMP00131
Gamma-glutamyl-transpeptidase deficiencyDiseaseSMP00501
Cholesteryl ester storage diseaseDiseaseSMP00508
Mercaptopurine Metabolism PathwayDrug metabolismSMP00609
Folate malabsorption, hereditaryDiseaseSMP00724
Canavan DiseaseDiseaseSMP00175
Tyrosinemia Type 2 (or Richner-Hanhart syndrome)DiseaseSMP00369
Clomocycline Action PathwayDrug actionSMP00262
Clarithromycin Action PathwayDrug actionSMP00248
Kanamycin Action PathwayDrug actionSMP00255
Demeclocycline Action PathwayDrug actionSMP00290
Minocycline Action PathwayDrug actionSMP00292
Troleandomycin Action PathwayDrug actionSMP00730
Aspartate MetabolismMetabolicSMP00067
Leigh SyndromeDiseaseSMP00196
Argininosuccinic AciduriaDiseaseSMP00003
Carbamoyl Phosphate Synthetase DeficiencyDiseaseSMP00002
Erythromycin Action PathwayDrug actionSMP00250
Telithromycin Action PathwayDrug actionSMP00252
Netilmicin Action PathwayDrug actionSMP00257
Tetracycline Action PathwayDrug actionSMP00294
Tigecycline Action PathwayDrug actionSMP00712
Paromomycin Action PathwayDrug actionSMP00714
Methacycline Action PathwayDrug actionSMP00727
HypoacetylaspartiaDiseaseSMP00192
PhenylketonuriaDiseaseSMP00206
Tyrosinemia Type 3 (TYRO3)DiseaseSMP00370
ArgininemiaDiseaseSMP00357
Clindamycin Action PathwayDrug actionSMP00249
Neomycin Action PathwayDrug actionSMP00256
Doxycycline Action PathwayDrug actionSMP00291
Oxytetracycline Action PathwayDrug actionSMP00293
Tobramycin Action PathwayDrug actionSMP00711
Arbekacin Action PathwayDrug actionSMP00713
Rolitetracycline Action PathwayDrug actionSMP00726
Josamycin Action PathwayDrug actionSMP00731
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)DiseaseSMP00334
Citrullinemia Type IDiseaseSMP00001
Roxithromycin Action PathwayDrug actionSMP00251
Amikacin Action PathwayDrug actionSMP00253
Spectinomycin Action PathwayDrug actionSMP00258
Lymecycline Action PathwayDrug actionSMP00295
Primary hyperoxaluria II, PH2DiseaseSMP00558
Warburg EffectMetabolicSMP00654
Lincomycin Action PathwayDrug actionSMP00728
Ammonia RecyclingMetabolicSMP00009
Phenylalanine and Tyrosine MetabolismMetabolicSMP00008
Pyruvate MetabolismMetabolicSMP00060
Pyruvate Dehydrogenase Complex DeficiencyDiseaseSMP00212
Urea CycleMetabolicSMP00059
Ornithine Transcarbamylase Deficiency (OTC Deficiency)DiseaseSMP00205
Azithromycin Action PathwayDrug actionSMP00247
Gentamicin Action PathwayDrug actionSMP00254
Streptomycin Action PathwayDrug actionSMP00259
Pyruvate kinase deficiencyDiseaseSMP00559
Chloramphenicol Action PathwayDrug actionSMP00729
Hyperprolinemia Type IDiseaseSMP00361
HypermethioninemiaDiseaseSMP00341
Tryptophan MetabolismMetabolicSMP00063
Beta Ureidopropionase DeficiencyDiseaseSMP00172
Creatine deficiency, guanidinoacetate methyltransferase deficiencyDiseaseSMP00504
Succinic semialdehyde dehydrogenase deficiencyDiseaseSMP00567
HomocarnosinosisDiseaseSMP00385
Prolidase Deficiency (PD)DiseaseSMP00207
Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)DiseaseSMP00188
Glycine N-methyltransferase DeficiencyDiseaseSMP00222
Pyrimidine MetabolismMetabolicSMP00046
Dihydropyrimidinase DeficiencyDiseaseSMP00178
Hyperornithinemia-hyperammonemia-homocitrullinuria [HHH-syndrome]DiseaseSMP00506
Methionine MetabolismMetabolicSMP00033
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase DeficiencyDiseaseSMP00243
Prolinemia Type IIDiseaseSMP00208
S-Adenosylhomocysteine (SAH) Hydrolase DeficiencyDiseaseSMP00214
UMP Synthase Deiciency (Orotic Aciduria)DiseaseSMP00219
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)DiseaseSMP00202
Hyperornithinemia with gyrate atrophy (HOGA)DiseaseSMP00505
Glutamate MetabolismMetabolicSMP00072
Arginine and Proline MetabolismMetabolicSMP00020
Hyperinsulinism-Hyperammonemia SyndromeDiseaseSMP00339
Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)DiseaseSMP00362
Ornithine Aminotransferase Deficiency (OAT Deficiency)DiseaseSMP00363
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)DiseaseSMP00340
2-Hydroxyglutric Aciduria (D And L Form)DiseaseSMP00136
L-arginine:glycine amidinotransferase deficiencyDiseaseSMP00507
Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism, cblG complementation typeDiseaseSMP00570
Molybdenum Cofactor DeficiencyDiseaseSMP00203
Purine Nucleoside Phosphorylase DeficiencyDiseaseSMP00210
SarcosinemiaDiseaseSMP00244
Hyperglycinemia, non-ketoticDiseaseSMP00485
Mitochondrial DNA depletion syndromeDiseaseSMP00536
Hyperprolinemia Type IIDiseaseSMP00360
Cystathionine Beta-Synthase DeficiencyDiseaseSMP00177
Methionine Adenosyltransferase DeficiencyDiseaseSMP00221
Purine MetabolismMetabolicSMP00050
Adenylosuccinate Lyase DeficiencyDiseaseSMP00167
Non Ketotic HyperglycinemiaDiseaseSMP00223
Azathioprine Action PathwayDrug actionSMP00427
Adenosine Deaminase DeficiencyDiseaseSMP00144
AICA-RibosiduriaDiseaseSMP00168
Glycine and Serine MetabolismMetabolicSMP00004
Thioguanine Action PathwayDrug actionSMP00430
Disulfiram Action PathwayDrug actionSMP00429
Myoadenylate deaminase deficiencyDiseaseSMP00537
Gout or Kelley-Seegmiller SyndromeDiseaseSMP00365
Dimethylglycine Dehydrogenase DeficiencyDiseaseSMP00242
Mercaptopurine Action PathwayDrug actionSMP00428
Xanthinuria type IDiseaseSMP00512
Lesch-Nyhan Syndrome (LNS)DiseaseSMP00364
Xanthine Dehydrogenase Deficiency (Xanthinuria)DiseaseSMP00220
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)DiseaseSMP00179
Dimethylglycine Dehydrogenase DeficiencyDiseaseSMP00484
Xanthinuria type IIDiseaseSMP00513
Adenine phosphoribosyltransferase deficiency (APRT)DiseaseSMP00535
3-Phosphoglycerate dehydrogenase deficiencyDiseaseSMP00721
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8672
Blood Brain Barrier+0.9035
Caco-2 permeable-0.7475
P-glycoprotein substrateNon-substrate0.6692
P-glycoprotein inhibitor INon-inhibitor0.8983
P-glycoprotein inhibitor IINon-inhibitor0.9763
Renal organic cation transporterNon-inhibitor0.9571
CYP450 2C9 substrateNon-substrate0.8379
CYP450 2D6 substrateNon-substrate0.8363
CYP450 3A4 substrateNon-substrate0.5673
CYP450 1A2 substrateNon-inhibitor0.8908
CYP450 2C9 substrateNon-inhibitor0.9403
CYP450 2D6 substrateNon-inhibitor0.9005
CYP450 2C19 substrateNon-inhibitor0.9352
CYP450 3A4 substrateNon-inhibitor0.9375
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.976
Ames testNon AMES toxic0.8933
CarcinogenicityNon-carcinogens0.9165
BiodegradationNot ready biodegradable0.9645
Rat acute toxicity2.5022 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9727
hERG inhibition (predictor II)Non-inhibitor0.8159
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point176 °CNot Available
water solubility1E+006 mg/LMERCK INDEX (1996); freely soluble
logP-5.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.49 mg/mLALOGPS
logP-0.84ALOGPS
logP-6ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)0.9ChemAxon
pKa (Strongest Basic)5ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area279.13 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity95.81 m3·mol-1ChemAxon
Polarizability38.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

George M. Whitesides, Patricia E. Garrett, Merrell G. Siegel, “Method for preparing adenosine triphosphate.” U.S. Patent US4164444, issued April, 1975.

US4164444
General Reference
  1. Gajewski E, Steckler DK, Goldberg RN: Thermodynamics of the hydrolysis of adenosine 5’-triphosphate to adenosine 5’-diphosphate. J Biol Chem. 1986 Sep 25;261(27):12733-7. Pubmed
  2. Storer AC, Cornish-Bowden A: Concentration of MgATP2- and other ions in solution. Calculation of the true concentrations of species present in mixtures of associating ions. Biochem J. 1976 Oct 1;159(1):1-5. Pubmed
  3. Wilson JE, Chin A: Chelation of divalent cations by ATP, studied by titration calorimetry. Anal Biochem. 1991 Feb 15;193(1):16-9. Pubmed
  4. Garfinkel L, Altschuld RA, Garfinkel D: Magnesium in cardiac energy metabolism. J Mol Cell Cardiol. 1986 Oct;18(10):1003-13. Pubmed
  5. Parsons M: Glycosomes: parasites and the divergence of peroxisomal purpose. Mol Microbiol. 2004 Aug;53(3):717-24. Pubmed
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSDownload (72.6 KB)
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. Abelson tyrosine-protein kinase 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Abelson tyrosine-protein kinase 2 P42684 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. ATP-binding cassette sub-family A member 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
ATP-binding cassette sub-family A member 1 O95477 Details

References:

  1. Porchay I, Pean F, Bellili N, Royer B, Cogneau J, Chesnier MC, Caradec A, Tichet J, Balkau B, Marre M, Fumeron F: ABCA1 single nucleotide polymorphisms on high-density lipoprotein-cholesterol and overweight: the D.E.S.I.R. study. Obesity (Silver Spring). 2006 Nov;14(11):1874-9. Pubmed
  2. Badeau R, Jauhiainen M, Metso J, Nikander E, Tikkanen MJ, Ylikorkala O, Mikkola TS: Effect of isolated isoflavone supplementation on ABCA1-dependent cholesterol efflux potential in postmenopausal women. Menopause. 2007 Mar-Apr;14(2):293-9. Pubmed
  3. Zarubica A, Trompier D, Chimini G: ABCA1, from pathology to membrane function. Pflugers Arch. 2007 Feb;453(5):569-79. Epub 2006 Jul 21. Pubmed

3. Acetyl-coenzyme A synthetase, cytoplasmic

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Acetyl-coenzyme A synthetase, cytoplasmic Q9NR19 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Starai VJ, Celic I, Cole RN, Boeke JD, Escalante-Semerena JC: Sir2-dependent activation of acetyl-CoA synthetase by deacetylation of active lysine. Science. 2002 Dec 20;298(5602):2390-2. Pubmed
  4. Schuler AJ, Jenkins D: Enhanced biological phosphorus removal from wastewater by biomass with different phosphorus contents, Part II: Anaerobic adenosine triphosphate utilization and acetate uptake rates. Water Environ Res. 2003 Nov-Dec;75(6):499-511. Pubmed

4. ALK tyrosine kinase receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
ALK tyrosine kinase receptor Q9UM73 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

5. NEDD8-activating enzyme E1 regulatory subunit

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
NEDD8-activating enzyme E1 regulatory subunit Q13564 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

6. 5'-AMP-activated protein kinase catalytic subunit alpha-1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
5'-AMP-activated protein kinase catalytic subunit alpha-1 Q13131 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

7. Serine/threonine-protein kinase A-Raf

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Serine/threonine-protein kinase A-Raf P10398 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

8. Serine/threonine-protein kinase receptor R3

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Serine/threonine-protein kinase receptor R3 P37023 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

9. Long-chain-fatty-acid--CoA ligase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Long-chain-fatty-acid--CoA ligase 1 P33121 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

10. Cytosolic purine 5'-nucleotidase

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Cytosolic purine 5'-nucleotidase P49902 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

11. ATPase ASNA1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
ATPase ASNA1 O43681 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

12. ATP-binding cassette sub-family C member 9

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
ATP-binding cassette sub-family C member 9 O60706 Details

References:

  1. Zhao JL, Yang YJ, You SJ, Jing ZC, Wu YJ, Cheng JL, Gao RL: Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Coron Artery Dis. 2006 Aug;17(5):463-9. Pubmed
  2. Yang YJ, Zhao JL, You SJ, Wu YJ, Jing ZC, Gao RL, Chen ZJ: Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATP channel. Eur J Heart Fail. 2007 Jan;9(1):30-6. Epub 2006 Jul 7. Pubmed
  3. Bryan J, Munoz A, Zhang X, Dufer M, Drews G, Krippeit-Drews P, Aguilar-Bryan L: ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch. 2007 Feb;453(5):703-18. Epub 2006 Aug 8. Pubmed

13. RAC-alpha serine/threonine-protein kinase

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
RAC-alpha serine/threonine-protein kinase P31749 Details

References:

  1. Van Meter TE, Broaddus WC, Cash D, Fillmore H: Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas. Cancer. 2006 Nov 15;107(10):2446-54. Pubmed

14. Beta-adrenergic receptor kinase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Beta-adrenergic receptor kinase 1 P25098 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

15. Apoptotic protease-activating factor 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Apoptotic protease-activating factor 1 O14727 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Chinnaiyan AM: The apoptosome: heart and soul of the cell death machine. Neoplasia. 1999 Apr;1(1):5-15. Pubmed

16. Acetyl-coenzyme A synthetase 2-like, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Acetyl-coenzyme A synthetase 2-like, mitochondrial Q9NUB1 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

17. Activin receptor type-1B

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Activin receptor type-1B P36896 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

18. Activin receptor type-1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Activin receptor type-1 Q04771 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

19. Bile salt export pump

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Bile salt export pump O95342 Details

References:

  1. Snow KL, Moseley RH: Effect of thiazolidinediones on bile acid transport in rat liver. Life Sci. 2007 Jan 30;80(8):732-40. Epub 2006 Nov 10. Pubmed
  2. Suchy FJ, Ananthanarayanan M: Bile salt excretory pump: biology and pathobiology. J Pediatr Gastroenterol Nutr. 2006 Jul;43 Suppl 1:S10-6. Pubmed

20. Asparagine synthetase [glutamine-hydrolyzing]

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Asparagine synthetase [glutamine-hydrolyzing] P08243 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

21. Cyclin-dependent kinase 15

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Cyclin-dependent kinase 15 Q96Q40 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

22. ADP/ATP translocase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
ADP/ATP translocase 1 P12235 Details

References:

  1. Walther T, Tschope C, Sterner-Kock A, Westermann D, Heringer-Walther S, Riad A, Nikolic A, Wang Y, Ebermann L, Siems WE, Bader M, Shakibaei M, Schultheiss HP, Dorner A: Accelerated mitochondrial adenosine diphosphate/adenosine triphosphate transport improves hypertension-induced heart disease. Circulation. 2007 Jan 23;115(3):333-44. Epub 2007 Jan 8. Pubmed

23. ATP-binding cassette sub-family C member 8

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
ATP-binding cassette sub-family C member 8 Q09428 Details

References:

  1. Nakamura A, Kawahito S, Kawano T, Nazari H, Takahashi A, Kitahata H, Nakaya Y, Oshita S: Differential effects of etomidate and midazolam on vascular adenosine triphosphate-sensitive potassium channels: isometric tension and patch clamp studies. Anesthesiology. 2007 Mar;106(3):515-22. Pubmed
  2. Bienengraeber M, Warltier DC, Bosnjak ZJ, Stadnicka A: Mechanism of cardiac sarcolemmal adenosine triphosphate-sensitive potassium channel activation by isoflurane in a heterologous expression system. Anesthesiology. 2006 Sep;105(3):534-40. Pubmed
  3. Bryan J, Munoz A, Zhang X, Dufer M, Drews G, Krippeit-Drews P, Aguilar-Bryan L: ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch. 2007 Feb;453(5):703-18. Epub 2006 Aug 8. Pubmed
  4. Tanaka K, Kawano T, Nakamura A, Nazari H, Kawahito S, Oshita S, Takahashi A, Nakaya Y: Isoflurane activates sarcolemmal adenosine triphosphate-sensitive potassium channels in vascular smooth muscle cells: a role for protein kinase A. Anesthesiology. 2007 May;106(5):984-91. Pubmed

24. Argininosuccinate synthase

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Argininosuccinate synthase P00966 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

25. AFG3-like protein 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
AFG3-like protein 2 Q9Y4W6 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

26. Beta-adrenergic receptor kinase 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Beta-adrenergic receptor kinase 2 P35626 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

27. Anti-Muellerian hormone type-2 receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Anti-Muellerian hormone type-2 receptor Q16671 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

28. Activated CDC42 kinase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Activated CDC42 kinase 1 Q07912 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

29. Tyrosine-protein kinase ABL1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Tyrosine-protein kinase ABL1 P00519 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

30. Adenylate cyclase type 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Adenylate cyclase type 1 Q08828 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

31. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Lage H: MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets. 2006 Jul;7(7):813-21. Pubmed
  2. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K: Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther. 2006 Aug;80(2):192-201. Pubmed
  3. Blume H, Donath F, Warnke A, Schug BS: Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29(9):769-84. Pubmed
  4. Gervasini G, Carrillo JA, Garcia M, San Jose C, Cabanillas A, Benitez J: Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. Cancer. 2006 Dec 15;107(12):2850-7. Pubmed
  5. Fukui N, Suzuki Y, Sawamura K, Sugai T, Watanabe J, Inoue Y, Someya T: Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit. 2007 Apr;29(2):185-9. Pubmed

32. ATP-binding cassette sub-family G member 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
ATP-binding cassette sub-family G member 1 P45844 Details

References:

  1. Lage H: MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets. 2006 Jul;7(7):813-21. Pubmed
  2. Materna V, Stege A, Surowiak P, Priebsch A, Lage H: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun. 2006 Sep 15;348(1):153-7. Epub 2006 Jul 14. Pubmed
  3. Thomas AC, Cullup T, Norgett EE, Hill T, Barton S, Dale BA, Sprecher E, Sheridan E, Taylor AE, Wilroy RS, DeLozier C, Burrows N, Goodyear H, Fleckman P, Stephens KG, Mehta L, Watson RM, Graham R, Wolf R, Slavotinek A, Martin M, Bourn D, Mein CA, O’Toole EA, Kelsell DP: ABCA12 is the major harlequin ichthyosis gene. J Invest Dermatol. 2006 Nov;126(11):2408-13. Epub 2006 Aug 10. Pubmed
  4. Girardin F: Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin Neurosci. 2006;8(3):311-21. Pubmed
  5. Pinkett HW, Lee AT, Lum P, Locher KP, Rees DC: An inward-facing conformation of a putative metal-chelate-type ABC transporter. Science. 2007 Jan 19;315(5810):373-7. Epub 2006 Dec 7. Pubmed

33. Canalicular multispecific organic anion transporter 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Canalicular multispecific organic anion transporter 1 Q92887 Details

References:

  1. Materna V, Stege A, Surowiak P, Priebsch A, Lage H: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun. 2006 Sep 15;348(1):153-7. Epub 2006 Jul 14. Pubmed
  2. Rau T, Erney B, Gores R, Eschenhagen T, Beck J, Langer T: High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006 Nov;80(5):468-76. Pubmed
  3. Li GX, Pei QL, Gao Y, Liu KM, Nie JS, Han G, Qiu YL, Zhang WP: Protective effects of hepatocellular canalicular conjugate export pump (Mrp2) on sodium arsenite-induced hepatic dysfunction in rats. Exp Toxicol Pathol. 2007 Aug;58(6):447-53. Epub 2007 Apr 30. Pubmed

Enzymes

1. Adenosine kinase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Adenosine kinase P55263 Details

References:

  1. Park J, Gupta RS: Adenosine kinase and ribokinase—the RK family of proteins. Cell Mol Life Sci. 2008 Sep;65(18):2875-96. Pubmed
  2. Leoncini R, Vannoni D, Santoro A, Giglioni S, Carli R, Marinello E: Adenosine kinase from rat liver: new biochemical properties. Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1107-12. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 24, 2013 14:20